GeneDx and Partners Secure $14.4M NIH Grant to Launch First U.S. Multi-State Genomic Newborn Screening Initiative

Reuters
2025/10/02
GeneDx and Partners Secure $14.4M NIH Grant to Launch First U.S. Multi-State Genomic Newborn Screening Initiative

**GeneDx Holdings Corp. and Partners Launch First U.S. National Genomic Newborn Screening Initiative with $14.4 Million NIH Grant** GeneDx Holdings Corp. (Nasdaq: WGS) has announced the launch of BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the nation's first multi-state genomic newborn screening initiative. The project is funded by a $14.4 million grant from the National Institutes of Health (NIH) Common Fund Venture Program, awarded jointly to multiple organizations including Mass General Brigham, Ariadne Labs, Boston Children's Hospital, Albert Einstein College of Medicine, the Association of Public Health Laboratories (APHL), Case Western Reserve University, Baylor College of Medicine, and Illumina. BEACONS will pilot the integration of whole genome sequencing into state newborn screening programs, recruiting up to 30,000 newborns across as many as 10 states over the next three years. This collaboration aims to evaluate the feasibility, ethical considerations, and potential public health impact of using genomic sequencing for newborn screening in the United States. If successful, the project could pave the way for expanding genomic screening nationwide.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20251001487540) on October 01, 2025, and is solely responsible for the information contained therein.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10